Advertise on podcast: OncologyEducation presents MedOncNow

Rating

★★★★★

from

1 reviews

Description

OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast. Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.

Unlock OncologyEducation presents MedOncNow podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from OncologyEducation presents MedOncNow podcast

A Waterfall of Options - Perioperative Bladder Cancer - Part 2

2026/09/23

In this episode of MedOncNow, Dr. Aly-Khan Lalani, walks us through the rapidly evolving landscape of perioperative therapy for muscle-invasive bladder cancer — two practice-changing trials, two different patient populations, and a whole lot of practical decisions that no algorithm will make for you. This is particularly timely given there is an access program for this Regimen.

A Waterfall of Options - Perioperative Bladder Cancer - Part 1

2026/09/08

Summiting Perioperative Gastric Cancer - With Dr. Howie Lim

2026/06/09

In this episode, Dr. Howard Lim takes us through the peri-operative management of Gastric/GEJ Adenocarcinoma. This is particularly timely given Ontario now has funded access to the Matterhorn regimen, with the hopes of other provinces to follow.

Abema and Ribo - Adjuvant High Risk EBC with Dr. Aalok Kumar

2026/05/13

In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.

Targeted therapy in Cholangiocarcinoma - Part 2 - Ivosidenib

2026/04/23

In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib (PART 1) to target FGFR2 fusions and Ivosidenib (PART 2) for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.

Targeted therapy in Cholangiocarcinoma - Part 1 - Pemigatinib

2026/04/02

In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib to target FGFR2 fusions and Ivosidenib for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.

You Are What You Eat - Diet and Cancer with Dr. Urvi Shah

2026/03/18

In this episode, Dr. Urvi Shah takes us through how to optimize diet in cancer treatment and prevention.

Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky

2026/02/06

In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib.

Choosing in Advanced NSCLC - Without AGA, and EGFR+ with Dr. Natasha Leighl

2026/01/19

In this episode, Dr. Natasha Leighl takes us through practical aspects of choosing treatments in advanced NSCLC without AGA and then in EGFR + NSCLC. We discuss treatments that are routinely available in clinic.

Sequencing in Advanced Colorectal Cancer - with Dr. Scott Berry

2025/12/23

In this episode, Dr. Scott Berry takes us through practical discussions on sequencing the increasing available treatment options for Advanced Colorectal cancer.

BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin

2025/11/24

As we now access Encorafenib + Cetuximab + Folfox via a Pfizer sponsored PSP for the he first line treatment Braf V600e mutated, RAS wt, dMMR/MSS metastatic Colorectal cancer, Dr. Rachel Goodwin takes us through the regimen, its practical use and efficacy and toxicity management.

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

2025/10/07

As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

2025/09/16

As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management

Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala

2025/09/11

In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management. This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC.

IPI/NIVO for mCRC with Dr. Sharlene Gill

2025/08/21

In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy.